BioCentury | Aug 16, 2010
Financial News

Medicago proposes private placement of units

...To be raised: C$7 million (US$6.8 million) Units: 17.3 million Price: C$0.41 (unit) Placement agents: Dundee Securities Corp....
BioCentury | Jul 28, 2008
Company News

Arius, Roche deal

...six-month operating loss of C$6.4 million (US$6.4 million). Aquilo Partners Inc.; Reedland Capital Partners; and Dundee Securities Corp....
BioCentury | Jul 4, 2005
Company News

Bioxalis Medica Inc., Procyon deal

...day the deal closed. Bioxalis' TVT-Dox liposomal doxorubicin is in preclinical development for solid tumors. Dundee Securities Corp....
Items per page:
1 - 3 of 3
BioCentury | Aug 16, 2010
Financial News

Medicago proposes private placement of units

...To be raised: C$7 million (US$6.8 million) Units: 17.3 million Price: C$0.41 (unit) Placement agents: Dundee Securities Corp....
BioCentury | Jul 28, 2008
Company News

Arius, Roche deal

...six-month operating loss of C$6.4 million (US$6.4 million). Aquilo Partners Inc.; Reedland Capital Partners; and Dundee Securities Corp....
BioCentury | Jul 4, 2005
Company News

Bioxalis Medica Inc., Procyon deal

...day the deal closed. Bioxalis' TVT-Dox liposomal doxorubicin is in preclinical development for solid tumors. Dundee Securities Corp....
Items per page:
1 - 3 of 3